Medicine
Exelon 13.3 mg/24 hours transdermal patch
Exelon 13.3 mg/24 hours transdermal patch is a prescription medicine containing Rivastigmine for transdermal use, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…
Key facts
- Active ingredient (INN)
- Rivastigmine
- Brand
- Exelon
- Strength
- 13.3 mg/24 hours
- Dosage form
- Transdermal patch
- Route
- Transdermal
- Packs
- 30 patches
- Marketing authorisation holder
- Sandoz
- Manufacturer
- Sandoz2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06DA03 Rivastigmine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 July 2007
- Identifiers
- RxCUI 725021, 725023, 725105 +3DailyMed set ID 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0, b6ed6d15-116d-4596-92ce-3414574d7ba0NDC 0078-0503, 66758-144Application NDA022083
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 patch in 1 carton / 24 h in 1 patch | 66758-144-31 | Sandoz | 3 October 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Rivastigmine 13.3 mg/24 hours transdermal patch.
Other strengths and forms of Rivastigmine
Clinical summary
Rivastigmine is a cholinesterase inhibitor indicated for treatment of mild, moderate, and severe dementia of the Alzheimer’s type (AD), among other approved uses. It is available as capsules and transdermal patches for oral use. MedsAcross supplies Rivastigmine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RivastigmineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Exelon prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Exelon: European public assessment report (EPAR) · European Medicines Agency
- Prometax: European public assessment report (EPAR) · European Medicines Agency
Need Exelon 13.3 mg/24 hours transdermal patch for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.